برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Givlaari (givosiran) Injection Date of Approval: November 20, 2019 Company: Alnylam Pharmaceuticals, Inc. Treatment for: Acute Hepatic Porphyria Givlaari (givosiran) is an aminolevulinate synthase 1-directed small interfering RNA (siRNA) indicated for the treatment of adults with acute hepatic porphyria (AHP). https://t.me/ppdprogram

➡️Fetroja (cefiderocol) Injection Date of Approval: November 14, 2019 Company: Shionogi & Co., Ltd. Treatment for: Complicated Urinary Tract Infections; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia Fetroja (cefiderocol) is a siderophore cephalosporin indicated for the treatment of complicated urinary tract infections (cUTI), hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Gram-negative microorganisms. https://t.me/ppdprogram

➡️Reblozyl (luspatercept-aamt) for Injection Date of Approval: November 8, 2019 Company: Celgene Corporation Treatment for: Anemia in Beta-Thalassemia; Anemia in Lower-Risk Myelodysplastic Syndromes Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation agent (EMA) for the treatment of: Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Limitations of Use: Reblozyl is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia. https://t.me/ppdprogram

➡️Ziextenzo (pegfilgrastim-bmez) Injection Date of Approval: November 4, 2019 Company: Sandoz Treatment for: Neutropenia Associated with Chemotherapy Ziextenzo (pegfilgrastim-bmez) is a PEGylated growth colony-stimulating factor biosimilar to Neulasta (pegfilgrastim) used to reduce the incidence of febrile neutropenia in patients treated with chemotherapy. https://t.me/ppdprogram

➡️Talicia (amoxicillin, omeprazole and rifabutin) Delayed-Release Capsules Date of Approval: November 4, 2019 Company: RedHill Biopharma Ltd. Treatment for: Helicobacter Pylori Infection Talicia (omeprazole magnesium, amoxicillin and rifabutin) is a fixed-dose combination of two antibiotics, (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole) for the treatment of Helicobacter pylori (H. pylori) infection. https://t.me/ppdprogram

➡️Biorphen (phenylephrine hydrochloride) Injection Date of Approval: October 21, 2019 Company: Eton Pharmaceuticals, Inc. Treatment for: Hypotension Biorphen (phenylephrine hydrochloride) injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of hypotension during anesthesia. https://t.me/ppdprogram

➡️Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Tablets Date of Approval: October 21, 2019 Company: Vertex Pharmaceuticals Incorporated Treatment for: Cystic Fibrosis Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is a triple combination regimen for the treatment of cystic fibrosis (CF) in patients ages 6 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data. https://t.me/ppdprogram

➡️Amzeeq (minocycline) Topical Foam Date of Approval: October 18, 2019 Company: Foamix Pharmaceuticals Treatment for: Acne Amzeeq (minocycline) is a topical foam formulation of the approved tetracycline drug minocycline indicated for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older. https://t.me/ppdprogram

➡️Secuado (asenapine) Transdermal System Date of Approval: October 11, 2019 Company: Noven Pharmaceuticals, Inc. Treatment for: Schizophrenia Secuado (asenapine) is a transdermal atypical antipsychotic formulation indicated for the treatment of adults with schizophrenia. https://t.me/ppdprogram

➡️Reyvow (lasmiditan) Tablets Date of Approval: October 11, 2019 Company: Eli Lilly and Company Treatment for: Migraine Reyvow (lasmiditan) is a serotonin (5-HT)1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. https://t.me/ppdprogram

➡️Quzyttir (cetirizine hydrochloride) Injection Date of Approval: October 4, 2019 Company: TerSera Therapeutics LLC Treatment for: Urticaria Quzyttir (cetirizine hydrochloride) is a histamine-1 (H1) receptor antagonist indicated for the treatment of acute urticaria in adults and children 6 months of age and older. https://t.me/ppdprogram

➡️Aklief (trifarotene) Topical Cream Date of Approval: October 4, 2019 Company: Galderma Treatment for: Acne Aklief (trifarotene) is a topical retinoid indicated for the treatment of acne vulgaris in patients 9 years of age and older. https://t.me/ppdprogram

➡️Rybelsus (semaglutide) Tablets Date of Approval: September 20, 2019 Company: Novo Nordisk Treatment for: Diabetes, Type 2 Rybelsus (semaglutide) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults with type 2 diabetes mellitus. https://t.me/ppdprogram

➡️Ibsrela (tenapanor) Tablets Date of Approval: September 12, 2019 Company: Ardelyx, Inc Treatment for: Irritable Bowel Syndrome Ibsrela (tenapanor) is a first-in-class, sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). https://t.me/ppdprogram

➡️Xenleta (lefamulin) Tablets and Injection Date of Approval: August 19, 2019 Company: Nabriva Therapeutics plc Treatment for: Pneumonia Xenleta (lefamulin) is a first-in-class, semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia (CABP). https://t.me/ppdprogram

➡️Rinvoq (upadacitinib) Extended-Release Tablets Date of Approval: August 16, 2019 Company: AbbVie Inc. Treatment for: Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Ulcerative Colitis, Ankylosing Spondylitis Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. https://t.me/ppdprogram

➡️Wakix (pitolisant) Tablets Date of Approval: August 14, 2019 Company: Harmony Biosciences, LLC Treatment for: Narcolepsy Wakix (pitolisant) is a histamine-3 (H₃) receptor antagonist/inverse agonist for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. https://t.me/ppdprogram

➡️(pretomanid) Tablets Date of Approval: August 14, 2019 Company: TB Alliance Treatment for: Tuberculosis, Resistant Pretomanid is a nitroimidazooxazine antimycobacterial indicated for use in combination with bedaquiline and linezolid (the BPaL regimen) for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). https://t.me/ppdprogram

➡️Accrufer (ferric maltol) Capsules - formerly Feraccru Date of Approval: July 25, 2019 Company: Shield Therapeutics plc Treatment for: Iron Deficiency Accrufer (ferric maltol) is a non-salt formulation of ferric iron for the treatment of iron deficiency in adults. https://t.me/ppdprogram

➡️Baqsimi (glucagon) Nasal Powder Date of Approval: July 24, 2019 Company: Eli Lilly and Company Treatment for: Hypoglycemia Baqsimi (glucagon) is a nasally administered antihypoglycemic agent indicated for the treatment of severe hypoglycemia in diabetes patients ages 4 years and older. https://t.me/ppdprogram